Immutep Ltd · ASX:IMM
Immutep — Investor Presentation (February 2021)
45 slides from Immutep's investor presentation, Feb 2, 2021
Slide 1: The global leader in developing LAG-3 therapeutics
For personal use only The global leader in developing LAG-3 therapeutics Corporate Presentation February 2021 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: Overview
Overview For personal use only Immutep is an innovative biotechnology Collaboration deals executed company developing novel with industry leaders immunotherapies for cancer and autoimmune diseases Global leadership position in LAG-3 with four product candidates in immuno-oncology and Corporate Strat
Slide 4: Directors & Officers
Directors & Officers For personal use only Russell J. Howard Pete A Meyers Grant Chamberlain Marc Voigt Prof. Frédéric Triebel Deanne Miller PhD Non-Executive Non-Executive Executive Director & MD PhD, Chief Operating Non-Executive Director & Deputy Director Chief Executive Chief Scientific Officer,
Slide 5: LAG-3 Overview
For personal use only LAG-3 Overview - The most promising immune checkpoint -
Slide 6: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview For personal use only Company Program Preclinical Phase I Phase II Phase III Total Trials Patients Agonist Eftilagimod 10 5 15 951 Alpha(4) BMS Relatlimab 10 26 2 38 10,528 LAG525 (leramilimab) 1 4 5 1,069 B.I. BI754111 4 1 5 849 Macrogenics MGD013 3 3 5 1054 Mer
Slide 7: Targeting LAG-3: Multiple Therapeutics in Numerous Diseases
Targeting LAG-3: Multiple Therapeutics in Numerous Diseases For personal use only LAG-3, an immune checkpoint, was discovered in 1990 by Immutep’s CMO and CSO Prof Frédéric Triebel. Immutep has four LAG-3 product candidates: IMMUNOSTIMULATION IMMUNOSUPPRESSION Efti IMP761 (APC Activator) (Agonistic
Slide 8: Immunotherapy Pipeline
Immunotherapy Pipeline* For personal use only Commercial Program Preclinical Phase I Phase II Late Stage(5) Market Size(6) Rights Metastatic Breast Cancer (Chemo – IO) US$29.9 billion AIPAC Non-Small-Cell Lung Carcinoma (IO – IO) (1) US$22.6 billion TACTI-002 Head and Neck Squamous Cell Carcinoma (I
Slide 9: Immutep Out-Licensed Immunotherapy Pipeline
Immutep Out-Licensed Immunotherapy Pipeline* For personal use only Commercial Program Preclinical Phase I Phase II Late Stage(1) Updates Rights/Partners Solid Tumors + Blood Cancer (IO-IO Combo) Triple Negative Breast Cancer (Chemo-IO Combo) Novartis currently has five Oncology Global Rights clinica
Slide 10: Eftilagimod Alpha (efti or IMP321)
For personal use only Eftilagimod Alpha (efti or IMP321)
Slide 11: Efti: Potential Pipeline in a Product
Efti: Potential Pipeline in a Product High intrinsic value For personal use only Unique APC activator (MHC II Agonist) Effective APC activation leads to immune activation (e.g. CD8 T cells) as shown by ex vivo and in vivo experiments, and in clinical studies Pipeline in a product - Not limited to a
Slide 12: AIPAC Phase IIb Update: Interim OS Results in Dec 2020
For personal use only AIPAC Phase IIb Update: - Exciting Interim OS Results in Dec 2020 -
Slide 13: Efti: AIPAC (Phase IIb) design
Efti: AIPAC (Phase IIb) design AIPAC: Active Immunotherapy PAClitaxel in HER2-/ HR+ metastatic breast cancer (MBC) For personal use only Primary endpoint includes: Fact sheet ✓ Conducted in 7 EU countries • Assessment of Progression-Free Survival (PFS) (note: no hypothesis testing) – presented Mar 2
Slide 14: AIPAC Phase IIb Clinical Results: Overall Survival
AIPAC Phase IIb Clinical Results Overall Survival – FU1 (60% events; cut-off: Sep 20) Improving trend for the overall population (IIT) as data matures For personal use only Currently 2.7 months difference in median OS Post-study treatment was similar with 80.7% (efti) and 83.9% (placebo) receiving a
Slide 15: AIPAC Subgroup 1: Age < 65 – PFS / OS / ORR
AIPAC Phase IIb Clinical Results Subgroup 1: < 65 years – PFS / OS / ORR Clinically meaningful absolute and relative improvement for all efficacy parameters, significance for OS For personal use only ESMO scale of magnitude* = level 4 (makes reimbursement very likely) ORR Patients with age < 65 yrs
Slide 16: AIPAC Subgroup 2: Low Monocytes – PFS / OS / ORR
AIPAC Phase IIb Clinical Results Subgroup 2: Low Monocytes – PFS / OS / ORR Clinically meaningful, absolute and relative improvement for all efficacy parameters, significance for PFS/OS For personal use only ESMO scale of magnitude* = level 4 (makes reimbursement very likely) Patients with low monoc
Slide 17: AIPAC Immune Monitoring on Fresh Blood
AIPAC Phase IIb Clinical Results Immune Monitoring on Fresh Blood (up to 70 patients) For personal use only Cytotoxic CD8+ T Cell count over time Stat. significant (p=0.020) (Mean + SEM million cells/L of blood; Correlation: OS and cytotoxic CD8+ p-value Wilcoxon) T cell count CD8 T cell count at 6
Slide 18: AIPAC Summary and Conclusions
AIPAC Phase IIb Clinical Results Summary and Conclusions For personal use only First time Proof of Principle an APC activator has shown meaningful Significant increase in cytotoxic T cell increase in Overall Survival (OS) in a numbers compared to placebo randomised setting Proof of Concept Path Forw
Slide 19: Updates on Anti-PD-1 Combinations
For personal use only Updates on Anti-PD-1 Combinations
Slide 20: Efti: TACTI-002 Trial in Different Cancers
Efti: TACTI-002 Trial in Different Cancers TACTI-002 evaluates the combination of efti with KEYTRUDA® For personal use only (pembrolizumab) in a PD-L1 all comer study. In collaboration with Key Results from 1st line non-small-cell lung ORR combination results Phase II carcinoma (NSCLC) (as at 8th Oc
Slide 21: TACTI-002 Results: 1st line NSCLC (Part A)
TACTI-002 Results(1) 1st line NSCLC (Part A) For personal use only Part A* - 1st line NSCLC stage 1 & 2 Part A* - 1st line NSCLC Best response: stage 1 & 2 120 Best response: iUPD/iCPD 100 100 iUPD/iCPD iSD best % change from baseline % change compared to baseline 75 iSD 60 iPR iPR iCR 50 40 iCR 20
Slide 22: TACTI-002 Results: Benchmarking 1st line NSCLC
TACTI-002 Results(1) Benchmarking - 1st line NSCLC For personal use only Pembro alone** PD-L1 (TPS) TACTI-002 (KN042/ KN001) All comer (with PD-L1 41%* (36%, regardless of 17-20% results) available PD-L1 test results) >= 50% 39.5% 54%* ORR >= 1% 27.3% 44%* 1-49% ~17% 33%* < 50% 14-19% 32%* * only pa
Slide 23: TACTI-002 Results: 2nd line HNSCC (Part C)
TACTI-002 Results(1) 2nd line HNSCC (Part C) For personal use only Part C* - 2nd line HNSCC Stage 1&2 100 Best response: * cut-off 8-Oct 2020, n=23 % change compared to start of therapy 80 iUPD/iCPD 60 iSD iPR 40 iCR 20 0 -20 -40 -60 -80 -100 0 9 18 27 36 45 54 63 72 weeks ➢ All (except one) pts wit
Slide 24: TACTI-002 Results: Benchmarking 2nd line HNSCC
TACTI-002 Results(1) Benchmarking – 2nd line HNSCC For personal use only PD-L1 (CPS) Pembro alone** TACTI-002* 17.3% 50%* ≥1 2% CR 16.7% CR* ORR 42.9%* (with PD-L1 results) 14.6% (35.7% regardless of available PD-L1 test results) * only patients evaluated where PD-L1 test results available (21 out o
Slide 25: TACTI-002 Results: 2nd line NSCLC (Part B)
Efti: TACTI-002 Results(1) 2nd line NSCLC (Part B) - Benchmarking For personal use only OS - Stage 1 - Part B - NSCLC • All patients included in this trial had progressed on 100 1st line therapy containing PD-1/PD-L1, confirmed by 2 consecutive scans. Probability of Survival • 85% of patients have P
Slide 26: Efti: INSIGHT-004 Trial in Solid Tumours
Efti: INSIGHT-004 Trial in Solid Tumours For personal use only INSIGHT-004 is a dose escalation study evaluating efti in combination with Bavencio ® (avelumab). Conducted as the 4th arm of the INSIGHT trial. In collaboration with I.K.F. Phase I Encouraging single Open label trial Key Results in pati
Slide 27: Efti: Current Strategic Potential & Plans
Efti: Current Strategic Potential & Plans For personal use only Efti is the ideal candidate to combine with Efti’s current data base includes(1): ✓ chemo and ✓ PD-1/PD-L1 antagonists Up to 219 patients Chemotherapy Eftilagimod PD-1 / PD-L1 Alpha in anti-PD-(L)1 combinations Pembrolizumab 272 patient
Slide 28: TACTI-002 Extension in 1st line NSCLC
TACTI-002 Extension in 1st line NSCLC Results(1) Design + Status For personal use only Eligibility • Available tumor 30 mg efti SC + Primary: ORR (iRECIST) tissue Part A: 200 mg pembrolizumab IV • ECOG 0-1 Secondary: PFS, OS, PK, 1st line met. NSCLC • Adequate Up to 12 months then biomarker, PD, saf
Slide 29: Trial in 1st line HNSCC
Trial in 1st line HNSCC Potential Design + Status For personal use only • HNSCC 1st line PD-1 antagonist • Available tumor Primary: ORR tissue incl. PD-L1 CPS results R Secondary: PFS, OS, PK, • ECOG 0-1 1:1 biomarker, PD, safety and 30 mg efti SC tolerability • Adequate organ + functions PD-1 antag
Slide 30: Efti Partnerships
Efti Partnerships For personal use only • EOC, an Eddingpharm spin-off holding the Chinese rights for efti, Phase I study in MBC ongoing with a Phase II trial in preparation (152 patients) • Milestone and royalty bearing partnership • Spin off from NEC, Japan: aims to develop cancer drugs discovered
Slide 31: Efti in COVID-19 Patients
For personal use only Efti in COVID-19 Patients
Slide 32: EAT COVID trial
EAT COVID trial For personal use only • Window of opportunity to boost the immune response prior to deterioration requiring intensive care unit (ICU) admission and mechanical ventilation • Goal is to: • prevent T cell exhaustion and profound lymphopenia • eradicate the COVID-19 virus • avoid any ext
Slide 33: EAT COVID trial
EAT COVID trial For personal use only EAT COVID is an investigator-initiated trial evaluating efti in hospitalised COVID-19 patients Aims to “push the gas” on a patient’s immune response to prevent severe COVID- Phase II 19 symptoms requiring intensive care and leading to respiratory failure and dea
Slide 34: Out-Licensed Immunotherapy Pipeline
For personal use only Out-Licensed Immunotherapy Pipeline
Slide 35: LAG525 (IMP701) for Cancer
LAG525 (IMP701) for Cancer For personal use only • Novartis holds an exclusive WW licence to develop and commercialise LAG525 (which is derived from Immutep’s antagonist antibody known as IMP701) • 1st and 2nd milestone payments received by Immutep in August 2015 (undisclosed) and August 2017 (US$1
Slide 36: GSK'781 (IMP731) for Autoimmune Diseases
GSK’781 (IMP731) for Autoimmune Diseases For personal use only • GSK holds an exclusive WW licence to develop and commercialise GSK’781 (which is derived from Immutep’s depleting antibody known as IMP731) • Up to ₤64 million in upfront payments and milestones, plus royalties • GSK portfolio review i
Slide 37: IMP761 - Autoimmune Diseases
For personal use only IMP761 - Autoimmune Diseases -
Slide 38: Broad potential in targeting auto-reactive memory T cells with IMP761
Broad potential in targeting auto-reactive memory T cells with IMP761 For personal use only THE PRESENT: FIGHTING THE SYMPTOMS Treating general inflammation: corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, -IL-23 mAbs THE FUTURE: FIGHTING THE CAUSE Treating the disease process: silencing the fe
Slide 39: Other Partnerships
For personal use only Other Partnerships
Slide 40: New collaboration with LabCorp
New collaboration with LabCorp For personal use only • Licence and Collaboration Agreement for immuno- Laboratory Corporation of America oncology products or services Holdings (LabCorp) is a leading global life sciences company focused on • Development of lab tests that may help oncologists guiding
Slide 41: Corporate Snapshot & Outlook
For personal use only Corporate Snapshot & Outlook
Slide 42: Corporate Snapshot
Corporate Snapshot For personal use only IMM (ASX) Ticker symbols IMMP (NASDAQ) Securities on issue(1) (as at 1 February 2021) 648.7 million ordinary shares Cash & Term Deposits ~A$54.9 million (US$42.3 million) (as at 31 December 2020) Market Cap(2) A$256.2 million (US$196.3 million) (as at 1 Febru
Slide 43: 2020 & 2021 News Flow
2020 & 2021 News Flow* For personal use only 2020 2021 ❑ Final data from AIPAC: 2nd OS follow up ✓ AIPAC – PFS, ORR, Overall Survival delivered ❑ Data from TACTI-002 Parts A, B and C ✓ US IND for MBC ❑ Recruitment & first data from TACTI-002 Part A ✓ TACTI-002 – recruitment & data delivered e.g. ext
Slide 44: Summary
Summary For personal use only Global leadership position in Multiple active clinical trials LAG-3 with four related (including partnered product candidates in candidates), with further immuno-oncology and significant data read-outs in autoimmune disease 2021 Compelling clinical data from Established
Slide 45: Thank You
For personal use only Thank You